Treatable traits in the NOVELTY study. Agustí, A., Rapsomaniki, E., Beasley, R., Hughes, R., Müllerová, H., Papi, A., Pavord, I. D., Van Den Berge, M., Faner, R., & for the NOVELTY Study Investigators Respirology, 27(11):929–940, November, 2022. ![Treatable traits in the NOVELTY study [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Abstract Background and objective Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real‐world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of ‘asthma’, ‘COPD’ or ‘asthma + COPD’. Methods The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large ( n = 11,226), global study that systematically collects data in a real‐world setting, both in primary care clinics and specialized centres, for patients with ‘asthma’ ( n = 5932, 52.8%), ‘COPD’ ( n = 3898, 34.7%) or both (‘asthma + COPD’; n = 1396, 12.4%). Results The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with ‘asthma’, ‘COPD’ and ‘asthma + COPD’, respectively ( p \textless 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity. Conclusion These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real‐world setting to date. , This study shows which treatable traits are present and/or absent in patients diagnosed with ‘asthma’, ‘COPD’ (chronic obstructive pulmonary disease) and ‘asthma + COPD’ in a global, observational study of more than 11,000 patients (NOVELTY), and how their prevalence changes with disease severity. See related Editorial
@article{agusti_treatable_2022,
title = {Treatable traits in the {NOVELTY} study},
volume = {27},
issn = {1323-7799, 1440-1843},
url = {https://onlinelibrary.wiley.com/doi/10.1111/resp.14325},
doi = {10.1111/resp.14325},
abstract = {Abstract
Background and objective
Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real‐world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of ‘asthma’, ‘COPD’ or ‘asthma + COPD’.
Methods
The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large (
n
= 11,226), global study that systematically collects data in a real‐world setting, both in primary care clinics and specialized centres, for patients with ‘asthma’ (
n
= 5932, 52.8\%), ‘COPD’ (
n
= 3898, 34.7\%) or both (‘asthma + COPD’;
n
= 1396, 12.4\%).
Results
The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with ‘asthma’, ‘COPD’ and ‘asthma + COPD’, respectively (
p
{\textless} 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity.
Conclusion
These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real‐world setting to date.
,
This study shows which treatable traits are present and/or absent in patients diagnosed with ‘asthma’, ‘COPD’ (chronic obstructive pulmonary disease) and ‘asthma + COPD’ in a global, observational study of more than 11,000 patients (NOVELTY), and how their prevalence changes with disease severity.
See related
Editorial},
language = {en},
number = {11},
urldate = {2024-05-30},
journal = {Respirology},
author = {Agustí, Alvar and Rapsomaniki, Eleni and Beasley, Richard and Hughes, Rod and Müllerová, Hana and Papi, Alberto and Pavord, Ian D. and Van Den Berge, Maarten and Faner, Rosa and {for the NOVELTY Study Investigators}},
month = nov,
year = {2022},
pages = {929--940},
}
Downloads: 0
{"_id":"jXkh7EY6Lrw8icj5J","bibbaseid":"agust-rapsomaniki-beasley-hughes-mllerov-papi-pavord-vandenberge-etal-treatabletraitsinthenoveltystudy-2022","author_short":["Agustí, A.","Rapsomaniki, E.","Beasley, R.","Hughes, R.","Müllerová, H.","Papi, A.","Pavord, I. D.","Van Den Berge, M.","Faner, R.","for the NOVELTY Study Investigators"],"bibdata":{"bibtype":"article","type":"article","title":"Treatable traits in the NOVELTY study","volume":"27","issn":"1323-7799, 1440-1843","url":"https://onlinelibrary.wiley.com/doi/10.1111/resp.14325","doi":"10.1111/resp.14325","abstract":"Abstract Background and objective Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real‐world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of ‘asthma’, ‘COPD’ or ‘asthma + COPD’. Methods The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large ( n = 11,226), global study that systematically collects data in a real‐world setting, both in primary care clinics and specialized centres, for patients with ‘asthma’ ( n = 5932, 52.8%), ‘COPD’ ( n = 3898, 34.7%) or both (‘asthma + COPD’; n = 1396, 12.4%). Results The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with ‘asthma’, ‘COPD’ and ‘asthma + COPD’, respectively ( p \\textless 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity. Conclusion These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real‐world setting to date. , This study shows which treatable traits are present and/or absent in patients diagnosed with ‘asthma’, ‘COPD’ (chronic obstructive pulmonary disease) and ‘asthma + COPD’ in a global, observational study of more than 11,000 patients (NOVELTY), and how their prevalence changes with disease severity. See related Editorial","language":"en","number":"11","urldate":"2024-05-30","journal":"Respirology","author":[{"propositions":[],"lastnames":["Agustí"],"firstnames":["Alvar"],"suffixes":[]},{"propositions":[],"lastnames":["Rapsomaniki"],"firstnames":["Eleni"],"suffixes":[]},{"propositions":[],"lastnames":["Beasley"],"firstnames":["Richard"],"suffixes":[]},{"propositions":[],"lastnames":["Hughes"],"firstnames":["Rod"],"suffixes":[]},{"propositions":[],"lastnames":["Müllerová"],"firstnames":["Hana"],"suffixes":[]},{"propositions":[],"lastnames":["Papi"],"firstnames":["Alberto"],"suffixes":[]},{"propositions":[],"lastnames":["Pavord"],"firstnames":["Ian","D."],"suffixes":[]},{"propositions":[],"lastnames":["Van","Den","Berge"],"firstnames":["Maarten"],"suffixes":[]},{"propositions":[],"lastnames":["Faner"],"firstnames":["Rosa"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["for the NOVELTY Study Investigators"],"suffixes":[]}],"month":"November","year":"2022","pages":"929–940","bibtex":"@article{agusti_treatable_2022,\n\ttitle = {Treatable traits in the {NOVELTY} study},\n\tvolume = {27},\n\tissn = {1323-7799, 1440-1843},\n\turl = {https://onlinelibrary.wiley.com/doi/10.1111/resp.14325},\n\tdoi = {10.1111/resp.14325},\n\tabstract = {Abstract \n \n Background and objective \n Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real‐world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of ‘asthma’, ‘COPD’ or ‘asthma + COPD’. \n \n \n Methods \n \n The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large ( \n n \n = 11,226), global study that systematically collects data in a real‐world setting, both in primary care clinics and specialized centres, for patients with ‘asthma’ ( \n n \n = 5932, 52.8\\%), ‘COPD’ ( \n n \n = 3898, 34.7\\%) or both (‘asthma + COPD’; \n n \n = 1396, 12.4\\%). \n \n \n \n Results \n \n The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with ‘asthma’, ‘COPD’ and ‘asthma + COPD’, respectively ( \n p \n {\\textless} 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity. \n \n \n \n Conclusion \n These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real‐world setting to date. \n \n , \n This study shows which treatable traits are present and/or absent in patients diagnosed with ‘asthma’, ‘COPD’ (chronic obstructive pulmonary disease) and ‘asthma + COPD’ in a global, observational study of more than 11,000 patients (NOVELTY), and how their prevalence changes with disease severity. \n \n See related \n Editorial},\n\tlanguage = {en},\n\tnumber = {11},\n\turldate = {2024-05-30},\n\tjournal = {Respirology},\n\tauthor = {Agustí, Alvar and Rapsomaniki, Eleni and Beasley, Richard and Hughes, Rod and Müllerová, Hana and Papi, Alberto and Pavord, Ian D. and Van Den Berge, Maarten and Faner, Rosa and {for the NOVELTY Study Investigators}},\n\tmonth = nov,\n\tyear = {2022},\n\tpages = {929--940},\n}\n\n","author_short":["Agustí, A.","Rapsomaniki, E.","Beasley, R.","Hughes, R.","Müllerová, H.","Papi, A.","Pavord, I. D.","Van Den Berge, M.","Faner, R.","for the NOVELTY Study Investigators"],"key":"agusti_treatable_2022","id":"agusti_treatable_2022","bibbaseid":"agust-rapsomaniki-beasley-hughes-mllerov-papi-pavord-vandenberge-etal-treatabletraitsinthenoveltystudy-2022","role":"author","urls":{"Paper":"https://onlinelibrary.wiley.com/doi/10.1111/resp.14325"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://api.zotero.org/users/6607533/collections/VKGURBGN/items?key=hSjrOPQRRHHWY81SKs6CEz45&format=bibtex&limit=100","dataSources":["upP78A3qvEd6tbHFm","zpWcq5jS35za3AmLx"],"keywords":[],"search_terms":["treatable","traits","novelty","study","agustí","rapsomaniki","beasley","hughes","müllerová","papi","pavord","van den berge","faner","for the novelty study investigators"],"title":"Treatable traits in the NOVELTY study","year":2022}